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Pregnancy produces a protective effect against breast cancer in women who had their
first full term pregnancy (FTP) in their middle twenties. The later in life the first delivery
occurs, the higher the risk of breast cancer development. Also, transiently during the post-
partum period, the risk of developing breast cancer increases.This transient increased risk
is taken over by a long-lasting protective period.The genomic profile of parous women has
shown pregnancy induces a long-lasting “genomic signature” that explains the preventive
effect on breast cancer. This signature reveals that chromatin remodeling is the driver of
the differentiation process conferred by FTP. The chromatin remodeling process may be
the ultimate step mediating the protection of the breast against developing breast cancer
in post-menopausal years.
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INTRODUCTION
Breast cancer affects women of all ages, races, and nationalities
(1–3). The worldwide incidence has increased 30–40% since the
1970s (1, 3–6). In the USA only, it is estimated that there will be
around 295,000 new cases of breast cancer in women in 2014 (7).
In the same year, 40,000 women in the USA will die of this disease
(7). Each year, approximately 13,000 women under the age of 40
are diagnosed with breast cancer. Of these, 1,000 will die of this
disease (8).
Epidemiological, clinical, and experimental data have uncov-
ered that one of the risks of developing breast cancer is the
reproductive history (9–14). Pregnancy exerts a protective effect
in women whose first child was born from their late teens to their
middle twenties. This protection is relative to the risk for nulli-
parous (no offspring) women (9). The postponement of the first
delivery increases the risk of developing breast cancer. This risk
reaches the same levels observed in nulliparous women when first
full term pregnancy (FTP) occurs between 30 and 34 years of age,
increasing even further after 35 years (9, 10).
The aggressive form of breast cancer called triple-negative
breast cancer is more common in young women under the age
of 40. It is not understood why young women are more likely to
be diagnosed with this aggressive form of breast cancer (15).
Despite the decrease of risk for breast cancer in lifetime, approx-
imately 30% of breast cancer patients are diagnosed up to 5 years
after giving birth (16). This window of susceptibility toward a
higher risk of developing breast cancer comes with a greater risk
of developing metastasis (16).
This review will address the mechanisms that determine the
long-lasting preventive effect of pregnancy against breast can-
cer, and the transient increase of risk in the years that follow
pregnancy.
FULL TERM PREGNANCY REDUCES BREAST CANCER RISK
In experiments performed in rats, which is the gold standard
animal model for induction of mammary gland differentiation,
pregnancy (which takes 21± 3 days) has to be completed in order
to prevent carcinogen-induced mammary cancer development. In
Sprague-Dawley rats, it has been demonstrated that when their
first pregnancy was interrupted 12 days after conception and can-
cer was induced by 7,12-Dimethylbenz(a)anthracene (DMBA)
21 days later, the number and weight of the tumors per animal
in pregnancy-interrupted rats and age-matched virgin rats were
similar. However, rats that completed their pregnancy had a sig-
nificantly reduced amount of tumors (17). Completion of the first
pregnancy results in significant differentiation of the mammary
gland. This differentiation advances even further with milk pro-
duction and secretion and persists until weaning (17, 18). After
weaning, the regression of the lobular structures occurs, and the
remaining cells exhibit acquisition of new features such as prolif-
erative rate reduction and increased capacity to repair carcinogen-
damaged DNA (17). These new features, which are structural,
functional and molecular in nature, persist in the mammary gland,
resulting in a significant reduction in cancer incidence in several
rat and mice strains (19, 20). Gene expression analysis of the rat
mammary gland identified a genomic signature that clearly distin-
guishes nulliparous (no offspring) from parous rodents. This gene
expression profile explains the almost total refractoriness of the
parous rat mammary gland to develop neoplasms after carcinogen
exposure (19, 21).
Epidemiological studies have demonstrated that a female’s
reproductive history is closely linked to breast cancer risk (9, 10,
13). The first FTP is an essential step for determining the fate of
the mammary gland in subsequent decades. Pregnancy exerts a
protective effect in women whose first child is born before the
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female reaches her mid-twenties (9, 22). Moreover, multiple FTPs
significantly decrease the risk even further, whereas postpone-
ment of the first delivery to the female’s mid-thirties increases
the risk compared to nulliparous women (9, 10). Pregnancy is
a hormonally complex process that only succeeds when there is
a perfect synchronization of the levels of estrogen, progesterone
and human Chorionic Gonadotropin (hCG), hormones that are
essential for the maintenance of pregnancy and breast develop-
ment in preparation for milk production. Primiparous women
younger than 25 years of age that have elevated levels of hCG
during the first trimester have a 33% decreased breast cancer
incidence in their post-menopausal years (13, 23). On the other
hand, high estrogen levels have been associated with increased risk
of developing breast cancer in pre and post-menopausal women
(13, 23–25). Positive feedback of estrogen secreted by ovarian
follicles (26), together with the surge of gonadotropin releasing
hormone (GnRH) and luteinizing hormone (LH) trigger ovula-
tion (27). After oocyte fertilization and implantation, estrogen and
progesterone are supplemented by chorionic gonadotropin. These
three hormones and others contribute to stimulate the mammary
gland development by undergoing cell proliferation and differ-
entiation of terminal end buds to organized lobular structures.
Final differentiation toward preparation of milk production is
achieved by secretion of prolactin that stimulates the production
of milk and oxytocin that enhances the secretory activity of the
alveolar cells in the mature mammary gland (18, 28). Comple-
tion of pregnancy and further breastfeeding induce long-lasting
anatomic and molecular changes in the mammary gland (19).
These changes result in a significant reduction in breast cancer
incidence (17, 29–32).
The above mentioned findings show that the first FTP occur-
ring during the high risk susceptibility window, but before expo-
sure to a carcinogen, prevents mammary cancer initiation. This
observation is equivalent to the widely reported protective effect
of an early first FTP in women (17, 19, 33). Discriminating
whether a first FTP (and lactation) produces protection by induc-
ing complete differentiation of the breast, or, on the other hand,
increases the chances of developing breast cancer in pre and post-
menopausal years, is still an active area of research and debate.
In Section “Mechanisms by Which Pregnancy may Protect Post-
menopausal Women from Developing Breast Cancer,” we describe
how pregnancy-induced epigenetic modifications that occur dur-
ing the period of high susceptibility lead to increased protection
against breast cancer.
MECHANISMS BY WHICH PREGNANCY MAY PROTECT
POST-MENOPAUSAL WOMEN FROM DEVELOPING BREAST
CANCER
In the past, we have addressed the morphological, physiological,
and genomic changes that occur during and as a consequence of
pregnancy. This hormonally induced differentiation of the breast
stamps a mark on breast cancer risk (21, 30, 33–36). The architec-
ture of the breast of women in their reproductive years is composed
of three main lobular structures that are classified on the basis of
their degree of development into lobules type 1 (Lob 1), lobules
type 2 (Lob 2) and lobules type 3 (Lob 3) (17, 37, 38). The breast of
nulliparous women is mainly composed of Lob 1, with moderate
formation of Lob 2, structures that appear with successive men-
strual cycles. Lob 3 structures can only be seen occasionally during
early reproductive years. After menopause, the breast regresses and
these results in an increase in the number of Lob 1 as a consequence
of the decline in Lob 2 and Lob 3 produced with aging (38).
The breast of both post-menopausal nulliparous and parous
women contains mainly Lob1 after the regression of the mam-
mary gland subsequent to lactation in the latter group. However,
despite its close morphological resemblance, these Lob 1 struc-
tures have to be different biologically as parous and nulliparous
women differ in their susceptibility to carcinogenesis (35). This
concept has been further clarified by showing differences in cell
types between these two groups (39).
The cells from the parous breast contain higher chromatin
condensation (heterochromatin), while the breast parenchyma
of post-menopausal nulliparous women contains predominantly
euchromatin nucleus (EUN) cells (39) (Figure 1), which did not
achieve the most differentiated stage due to the absence of a FTP.
Therefore, this tissue retains its susceptibility to be transformed.
As a consequence, a carcinogenic insult or an inappropriate hor-
monal stimulus, such as hormone replacement therapy (40), have
the potential to transform the EUN cells into a breast cancer stem
cell. Thus, a differentiated cell, such as a EUN cell, has the ability to
re-acquire self-renewal potential (41, 42). This concept has been
further discussed in other experimental models (31, 43–45).
Since the initial finding by Al-Hajj et al. reporting that a small
population of CD44+CD24−/low breast cancer cells had the ability
to form new tumors with as few as a couple hundred cells whereas
tens of thousands of cells with alternate phenotypes failed to pro-
duce tumors (46), there has been active discussion in the hypothe-
sis of stem cell origin of breast cancer. Normal stem cells self-renew
and give rise to phenotypically diverse cells with reduced pro-
liferative potential (47). The tumorigenic CD44+CD24−/low cell
population is also able to proliferate extensively, and give rise
to diverse cell types with reduced proliferative potential (46).
By using a xenograft model, Al-Hajj et al. demonstrated that as
few as 200 sorted and passaged CD44+CD24−/low breast cancer
stem cells had the ability to produce tumors that could be seri-
ally transplanted in NOD/SCID mice (46). This and other groups
have since presented evidence showing that deregulation of self-
renewal in stem/progenitor cells may be a key event in mammary
tumorigenesis (48–50).
It is generally agreed that the involuted gland in the parous after
pregnancy and lactation resembles that of a virgin/nulliparous
at the morphological level (51). However, several physiologic,
genetic, and epigenetic changes have been noted when comparing
parous vs. nulliparous breast epithelium (34, 36, 44). In transplan-
tation studies,Wagner et al. showed that the parity-induced epithe-
lial population acquires self-renewal properties and contributes to
the reconstitution of ductal morphogenesis and lobulogenesis at
post-weaning (44). This period of lobular regression is accompa-
nied by a reduction in the proliferative rate, greater capabilities of
DNA repair and lower DNA affinity for carcinogens (52). It has
been proposed that the initial normal progenitor or stem cell 1
is present in the terminal end buds (35). These cells are thought
to give origin to the parenchymal tree but when these stem cells
1 are hit by a carcinogen, they become cancer stem cells. With
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FIGURE 1 | Epithelial cells of nulliparous and parous post-menopausal
breast. As observed with hematoxylin and eosin staining (H&E), the cells
from nulliparous breast (left) contain nuclei with less condensed chromatin
(euchromatin) compared to the nuclei of parous women (right). The parous
breast contains darker nuclei as a consequence of chromatin compactation
(heterochromatin). Immunohistochemistry revealed higher levels of
dimethylation of lysine 9 and trimethylation of lysine 27 in histone 3
(H3K9me2 and H3K27me3) in the parous breast, which have been linked
with gene silencing due to chromatin condensation.
aging and in the absence of previous pregnancy/pregnancies, the
parenchyma remains undifferentiated and susceptible to carcino-
gens. Early pregnancy induces the differentiation of the normal
stem cell 1 or progenitor cell into a more differentiated stem
cell 2, which is resistant to transformation. This stem cell 2 is
still capable of regenerating the gland on subsequent pregnan-
cies in preparation for lactation (35). Gene analysis has identified
a “genomic mark” that is sufficient to differentiate nulliparous
from parous tissue (34, 35, 44, 53, 54). These differences help to
explain the high refractoriness of the parous mammary gland to
develop carcinomas (19, 21, 39, 52, 53). This genomic signature in
the parity-induced cell population contributes significantly to the
biological differences between the mammary glands of parous and
nulliparous females, differences, which are long-lasting and thus
protect parous women from developing breast cancer.
PLU-1 is expressed in 90% of breast carcinomas and is asso-
ciated with malignant progression (55, 56). This nuclear protein
belongs to the ARID family of proteins, known to play essential
regulatory roles in development, differentiation, and chromatin
remodeling (57). In the normal mammary gland, mPlu-1 mRNA
is expressed at pregnancy, suggesting a role in proliferation in
the developing and differentiating mouse tissue (56). Microarray
analysis, after over expression or silencing of PLU-1, has identified
specific genes downregulated in mammary epithelial cells such
as BRCA1 and genes associated with cell cycle and spindle check-
points, confirming PLU-1’s function as a transcriptional repressor.
Barrett et al. investigated the interactions of PLU-1 with HDACs
and their interacting co-repressors. They demonstrated that PLU-
1 interacts directly with class I and II HDACs (58). Physiological
relevance of this protein in the mammary gland has been reported
as it is only expressed in pregnancy and regressing mouse mam-
mary gland but it is silenced during lactation (58). Significantly,
high expression of this protein is seen in the great majority of
breast cancers (55, 56).
During mammary remodeling related to the menstrual cycle,
pregnancy, and lactation, hormones contribute to the develop-
ment of a mature mammary gland with a definite structure (18,
59–62). Trithorax (TrxG) and Polycomb (PcG) group proteins are
required for gland preservation, acting epigenetically by regulating
gene expression through DNA methylation, histone modification,
and chromatin remodeling (63, 64). Perturbations in these epi-
genetic regulators are linked to the disruption of epithelial cell
identity and mammary gland remodeling, leading to breast cancer
initiation (65).
Consistently with higher levels of chromatin condensation
observed in the parous groups, the epithelial cells of this group
present more dimethylation of histone 3 in lysine 9 (H3K9me2)
and trimethylation of histone 3 in lysine 27 (H3K27me3) (39)
(Figure 1). Histone methylation plays a major role in marking
transcriptionally active and inactive regions of the genome and
associated chromatin, and is crucial in the key events that lead to
the development of the mammary gland (66).
Moreover, the parous breast shows up-regulation of chromatin
remodeling genes such as Chromodomain helicase DNA-binding
protein 2 (CHD2) and Chromobox homolog 3 (CBX3) (36, 39).
These proteins are required for controlling recruitment of histones
and transcription factors and consequently regulate transcription.
CBX3 is involved in heterochromatin-like complexes by recog-
nizing and binding H3 tails methylated at lysine 9. This leads to
transcriptional silencing of CBX3 target genes. Two other epige-
netic markers related to the PcG that are up-regulated in the parous
breast are L(3)mbt-like1 (L3MBTL) and Enhancer of zeste 2 poly-
comb repressive complex 2 subunit (EZH2) (36, 39). Members
of the PcG form multimeric protein complexes that maintain the
transcriptional repressive state of genes over successive cell gener-
ations. EZH2 is a histone-lysine-N -methytransferase, which acts
as a gene silencer by adding three methyl groups to lysine 27 of
histone 3, a modification that leads to chromatin condensation
(67–69).
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Recent studies have demonstrated that some non-coding RNA
molecules are at the center of nuclear assembly and recruit PcG
complexes to the locus of transcription (70). Indeed, up-regulation
of long non-coding RNAs (lncRNAs) was observed in the breast
of parous women (36, 39). Among the lncRNAs up-regulated
in the parous women were XIST (X inactive specific transcript),
NEAT1 (Nuclear paraspeckle assembly transcript 1), and MALAT1
(Metastasis-associated lung adenocarcinoma transcript 1) (36,
39). The last two lncRNAs have critical roles in assembly and
maintenance of the paraspeckles (71, 72). Further studies eval-
uated the expression levels of lncRNAs in the breast of healthy
post-menopausal women and identified 42 lncRNAs differentially
expressed between parous and nulliparous women (73, 74). Of
which, 21 were up-regulated and 21 were downregulated in the
parous. An additional eight non-coding regions presented statis-
tically significant correlation in expression with their nearby gene,
indicating a possible role of the lncRNA as a cis-regulatory element
(74). The above evidence places lncRNAs as potential players in
the regulation of chromatin transformation that occurs during
differentiation.
The spliceosome machinery, stored in the nuclear paraspeckles,
plays a critical role in the differentiation process of mouse embry-
onic stem cells (75). Post-transcriptional modifications of RNA,
and recognition by RNA-binding proteins and/or microRNAs
are crucial processes in differentiating breast epithelial cells (76).
Among the components of the spliceosome that are up-regulated
in the post-menopausal parous breast are the heterogeneous
nuclear ribonucleoproteins HNRPA3, HNRPA2B1, HNRPD, and
HNRPU (36). These HNRPs may be involved in mRNA process-
ing and stability, in addition to other cellular functions such as
mammary gland involution, regulation of telomere length main-
tenance (77), and/or mRNA trafficking (78). Other members of
the spliceosome machinery, also up-regulated in the parous breast,
are the small nuclear ribonucleoproteins (snRNPs) (36, 39). The
snRNPs function as suppressors of tumor cell growth (36, 39)
and may have major implications as cancer therapeutic targets.
For example, U1 snRNP is an essential component of the splicing
complex and has a key role in mRNA processing. Manipulating
U1 snRNP’s function could lead to therapeutic purposes in cancer
(79). Last, another component of the spliceosome complex that
regulates genes involved in the apoptotic process is RBM5 (RNA-
binding motif protein 5) (36, 39). RBM5 overexpression causes
cell cycle arrest, apoptosis, and inhibition of tumor growth (80). It
is also reported to enhance p53-mediated inhibition of cell growth
and colony formation (81). Part or all of these mechanisms could
also operate in the parous breast.
Cyclin L1 (CCNL1) and L2 (CCNL2) interact with splicing fac-
tors localized in the nuclear speckles (82). The epithelial cells in the
Lob 1 structures of the parous breast have been reported to present
overexpression of CCNL2 protein (39). CCNL1 and CCNL2 are
transcriptional regulators which participate not only in the pre-
mRNA splicing process (82) but also in the expression of factors
that lead to tumor cell growth inhibition and programed cell death,
possibly through the Wnt signaling transduction pathway (82, 83).
Of interest, the Wnt/β-catenin signaling pathway was found dif-
ferentially methylated between parous and nulliparous women,
indicating a lower production and accumulation of β-catenin in
the parous women (84, 85). This decrease in β-catenin may be
a leftover effect from mammary involution, which may represent
an additional safeguard mechanism occurring in the last steps of
mammary gland remodeling (84, 85).
The chromatin modifications observed in the parous breast are
accompanied by higher expression of genes related to cell adhesion
and differentiation, such as laminins, desmocollin-3, cytokeratin
5, and GATA binding protein 3 (GATA3) (34, 36, 39).
Finally, numerous downstream genes that are regulated by
the estrogen receptor α (ER-α) were found to be up-regulated
in the parous breast (36). Among these was GATA3, gene that
encodes for a protein which belongs to the GATA family of
transcriptional regulators. GATA family regulates T lymphocyte
differentiation and maturation. Specifically, GATA3 is key to the
morphogenesis of the mammary gland, driving the differentia-
tion of progenitor cells (86). It is also a putative tumor suppressor
(86). Therefore, the observation that genes involved in the ER reg-
ulated pathways are up-regulated in the parous breast suggests
that ER-α mediated genes could be under permanent transcrip-
tional modification as a manifestation of a higher degree of cell
differentiation.
The regulatory mechanisms highlighted in this section are
key to the decrease in susceptibility of the epithelial cell to car-
cinogenesis. However, more studies need to be conducted to
identify the specific pathways involved in this process. Data dis-
cussed here emphasizes the relevance of transcriptional and post-
transcriptional regulatory mechanisms as critical to the differ-
entiation of the breast. Increasing amount of data is revealing
how the combination of genetic and epigenetic modifications is
responsible for driving transformation, eventually leading to can-
cer. Therapeutic strategies that target a combination of genetic
mutations together with chromatin modifications, splicing fac-
tors, and lncRNA regulation will lead to more effective treatments.
In addition, agents which induce changes in the breast cells sim-
ilar to those induced by pregnancy could potentially be used to
protect healthy women considered at high risk of breast cancer
(BRCA 1/2 mutation carriers). One example is hCG,which induces
cell differentiation in the mammary gland in Sprague-Dawley
rats (87).
BASIS OF THE DUAL EFFECT OF PREGNANCY IN THE
PREMENOPAUSAL WOMAN
The differences in gene expression between parous and nulli-
parous women were also studied in premenopausal women (88).
Gene expression profile of breast tissue from 30 nulliparous and
79 parous premenopausal volunteers between the ages of 30 and
47 years of age, who were free of breast pathology at the moment
of biopsy, was analyzed. Because of the known transient increase
in breast cancer risk preceding the long-term protective effect of
FTP, the authors also examined gene expression differences in
parous vs. nulliparous women as a function of time since last
FTP. The results show 286 genes differentially expressed (fold-
change≥1.2 and false discovery rate<10%) comparing all parous
vs. all nulliparous, and/or, parous women whose last FTP was
less than 5 years before biopsy vs. all nulliparous women. Among
these, 238 genes were up-regulated, and 48 genes were downreg-
ulated in parous compared to nulliparous breast. Of interest is
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that the up-regulated genes presented three expression patterns:
(1) transient: genes up-regulated after FTP but whose expres-
sion levels rapidly returned to nulliparous levels. These genes
were mainly related to immune response; (2) long-term chang-
ing: genes up-regulated following FTP, whose expression lev-
els decreased with increasing time since last FTP but did not
return to nulliparous levels. These genes included genes related
to immune response and development; (3) long-term constant:
genes that remained up-regulated in parous compared to nulli-
parous breast, independent of time since last FTP. These genes were
mainly involved in developmental processes, cell differentiation,
and chromatin remodeling. This study shows that a FTP induces
long-term expression changes in genes related to the processes
of development, cell differentiation, and chromatin remodeling
(88) as has also been found in the parous post-menopausal breast
(34, 36, 39, 84).
It is not surprising that during the first 5 years after FTP, acti-
vation of several genes related to immune response is observed.
Growth factors, hormonal signaling and cytokines/chemokines are
known to participate in mammary gland differentiation and lac-
tation (89). However, these transiently activated genes may play a
role in the short-term increase of breast cancer risk following FTP
(88). Some of these genes showed large differences in expression
among the parous women, and that could be one of the explana-
tions why some women develop breast cancer soon after their FTP.
Rotunno et al. studied the gene expression between parous and
nulliparous, including premenopausal women (mean age= 37),
and observed a significant amount of genes associated to immu-
nity, inflammation, and wound responses (90). The inflamma-
tory microenvironment as well as the wound response genes
could contribute to the development of breast cancer in certain
women (90, 91).
CONCLUSION
Pregnancy exerts a protective effect in women who had an early
FTP. However, approximately 30% of breast cancer patients are
diagnosed up to 5 years after giving birth (16).
The genomic profile of nulliparous and parous women in the
premenopausal and post-menopausal period have shown that
some groups of genes are only activated during the first years
after FTP (88), while others are part of a long-lasting signature
(34, 36, 39, 84). Genes, which are only activated during the first
5 years after pregnancy (88), may contribute to the increased risk
experimented by some women after pregnancy. On the contrary,
the long-lasting signature induced by the FTP observed in the
pre and post-menopausal women explains pregnancy’s preventive
effect. Evidence point toward chromatin remodeling being the
major molecular mechanism that explains pregnancy’s preventive
effect (39, 84) (Figure 1). A better understanding of the molecular
effects of parity on the breast may help the development of novel
strategies for preventing breast cancer.
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